Current Report Filing (8-k)
June 07 2016 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 7, 2016
IMMUNOCELLULAR THERAPEUTICS, LTD.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-35560
|
|
93-1301885
|
(State or other jurisdiction
of incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
23622 Calabasas Road, Suite 300
Calabasas, California 91302
(Address of Principal Executive Offices) (Zip Code)
Registrants telephone number, including area code: (818) 264-2300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On June 7, 2016, ImmunoCellular Therapeutics, Ltd. (the Company) announced that the first patient has been treated in the
phase 3 registrational trial of ICT-107, the Companys lead cancer immunotherapy product candidate, in newly diagnosed glioblastoma.
ICT-107
is a patient-specific, dendritic cell-based immunotherapy
targeting multiple tumor-associated antigens on glioblastoma stem cells. The phase 3 trial is designed as a randomized, double-blind, placebo-controlled study of 414 HLA-A2-positive subjects, which will be conducted at approximately 120 sites in the
United States, Canada and the European Union. The primary endpoint in the trial is overall survival, which the U.S. Food and Drug Administration and European Union regulators have identified as an appropriate endpoint for registrational clinical
studies in glioblastoma. Secondary endpoints include progression-free survival and safety, as well as overall survival in the two pre-specified MGMT subgroups.
Cautionary Statement Regarding Forward-Looking Statements
This Current Report on Form 8-K contains certain forward-looking statements that are subject to a number of risks and uncertainties,
including the risk that ICT-107 can be further successfully developed or commercialized and whether the results will support registration filings with the U.S. Food and Drug Administration or European Medicines Agency. Additional risks and
uncertainties are described in the Companys most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, the Company undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 7, 2016
|
|
|
|
IMMUNOCELLULAR THERAPEUTICS, LTD.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ David Fractor
|
|
|
|
|
|
|
David Fractor
|
|
|
|
|
|
|
Vice President, Finance and Principal Accounting Officer
|
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Mar 2024 to Apr 2024
EOM Pharmaceutical (PK) (USOTC:IMUC)
Historical Stock Chart
From Apr 2023 to Apr 2024